Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Trevogrumab Formulations in Healthy Subjects
NCT02741739Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Mar 2016
- Primary completion
- Apr 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of trevogrumab in Sarcopenia and muscle atrophy (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Serum REGN1033 concentration-time curve at Day 57 and Peak REGN1033 concentration at Day 57. Started Mar 2016; status: completed.
02
Drugs
trevogrumab
03
Conditions
Sarcopeniamuscle atrophy
Beyond the preview
Go deeper on NCT02741739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02741739.